hero image
Connie Kang, PharmD, BCPS, BCGP - USC School of Pharmacy. Los Angeles, CA, US

Connie Kang, PharmD, BCPS, BCGP Connie Kang, PharmD, BCPS, BCGP

Assistant Professor of Clinical Pharmacy | USC School of Pharmacy


An expert in teaching and learning, curriculum and instruction, and community/hospice/inpatient/student health pharmacy practice.

Social Media


Connie Kang, PharmD, BCPS, BCGP, has joined the faculty of the Titus Department of Clinical Pharmacy as assistant professor of clinical pharmacy (clinician educator). Kang comes to USC from the KGI School of Pharmacy and Health Sciences where she was an assistant professor since July 2014. Prior to that, she worked as a pharmacist in a broad range of practice settings.

Kang is a board-certified pharmacotherapy specialist and certified geriatric pharmacist and holds a Doctor of Pharmacy from University of the Pacific. She currently is finishing her Doctor of Education in Curriculum and Instruction at University of the Pacific. Her research interests include action research in the classroom and understanding student learning.

Areas of Expertise (5)

Curriculum Development

Geriatric pharmacy

Clinical Pharmacy


Action Research

Education (2)

University of the Pacific: EdD

University of the Pacific: PharmD

Affiliations (2)

  • Board Certified Pharmacotherapy Specialist
  • Certified Geriatric Pharmacist

Selected Articles (1)

Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer


Connie Kang, Sohita Dhillon, Emma D. Deeks

2019 Trifluridine/tipiracil (Lonsurf®) is a fixed-dose combination tablet comprising trifluridine, an antineoplastic nucleoside analogue, and tipiracil, a thymidine phosphorylase inhibitor. Trifluridine/tipiracil has recently been granted an additional indication in the USA for the treatment of metastatic gastric cancer, including gastroesophageal junction adenocarcinoma, in patients who have been previously treated with at least two systemic treatment regimens, and has received a positive opinion for this indication in the EU. In the large pivotal phase III TAGS trial, trifluridine/tipiracil plus best supportive care (BSC) significantly prolonged overall survival (OS; primary endpoint) compared with placebo plus BSC in this patient group. Progression-free survival (PFS) and the disease control rate were also improved with trifluridine/tipiracil relative to placebo. Health-related quality of life was not adversely affected by the addition of trifluridine/tipiracil to BSC and time to deterioration of Eastern Cooperative Oncology Group (ECOG) performance status was significantly delayed. The most common adverse events were mainly haematological (neutropenia, leucopenia and anaemia) and gastrointestinal (nausea, vomiting and diarrhoea), and were generally manageable with dosage modifications and/or supportive care. Adverse events ≥ Grade 3 were most frequently haematological in nature. Thus, trifluridine/tipiracil provides a valuable and much needed treatment option for patients with metastatic gastric or gastroesophageal junction adenocarcinoma that has progressed on at least two prior therapies.

view more